CD47 and anemia: We further discuss implications for immunotherapy, noting that agents like magrolimab (anti-CD47) combined with azacitidine have demonstrated objective response rates (ORR) exceeding 80% in early-phase AML trials, though challenges such as on-target anemia persist.